Oct 23 (Reuters) - Valeant Pharmaceuticals Inc shares rebounded on Friday following four days of steep losses triggered by allegations it used specialty pharmacies to inflate revenue, which the company plans to refute in detail on Monday.
Following are the key stories on the company, whose shares have lost half their market value since an August peak:
LATEST STORIES > Valeant vows to refute "phantom sales" allegations > Share price meltdown wipes $1.5 bln from CEO's wealth > Slump poses big threat to small hedge funds > Looming M&A hiatus deals blow to investment banks > Plunge spotlights cracks in specialty pharma's M&A facade > Shares plunge on short-seller scrutiny > Specialty pharmacies in spotlight > Class action lawsuit filed against Valeant > Valeant's unusual CEO comes under fire > US CORP BOND WRAP-Healthcare rocked by more bad news > Falling secondary loan price pulls pharma down > Options volume explodes as traders dive for cover > Citron report on Valeant drags down biotechs
EARLIER STORIES > Meltdown costs investors billions; Ackman ups stake > CEO sees new drug pricing environment ahead > Clinton urges U.S. regulators to examine price hikes > Valeant subpoenaed by U.S. prosecutors
OPINION > Valeant sets tone for accounting scrutiny (Compiled by Nick Zieminski)